SCHEMBL4947260

SCHEMBL4947260

COc1cc(N)c2c(c1)CCCN2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.39
ACHE P22303 1/20 0.39
HSD17B10 Q99714 1/20 0.35
MAPKAPK2 P49137 2/20 0.35
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
THRB P10828 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP3A4 P08684 1/20 0.33
KDR P35968 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
KDM1A O60341 1/20 0.33
DNMT1 P26358 1/20 0.33
CDK1 P06493 1/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870174 0.81 PARP1 (0.40) PARP1ACHEHSD17B10MAPKAPK2ALDH1A1
SCHEMBL11701223 0.81 PARP1 (0.40) PARP1ACHEALDH1A1MEN1KMT2A
SCHEMBL4947965 0.77 KDM4E (0.33) PARP1HSD17B10ALDH1A1MEN1MAPT
SCHEMBL3941319 0.75 ACHE (0.41) PARP1ACHEHSD17B10ALDH1A1MEN1
SCHEMBL4941638 0.74 MEN1 (0.39) PARP1HSD17B10ALDH1A1MEN1MAPT
SCHEMBL4947364 0.74 PARP1 (0.36) PARP1HSD17B10ALDH1A1MEN1MAPT
SCHEMBL9396807 0.73 PARP1 (0.40) PARP1
SCHEMBL18602594 0.73 PARP1 (0.36) PARP1HSD17B10ALDH1A1MAPTTHRB
SCHEMBL20898042 0.71 SRC (0.38) PARP1HSD17B10MAPKAPK2ALDH1A1CYP3A4
SCHEMBL9035419 0.71 ACHE (0.46) PARP1ACHEHSD17B10MAPKAPK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1994028863-A1 8-AMINO-1,2,3,4-TETRAHYDROQUINOLINES AS COUPLERS IN DYES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1994-12-22 WO claimed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
US-9745299-B2 Substituted tricyclic benzimidazoles as kinase inhibitors SELVITA SA (PL) 2017-08-29 US disclosed
EP-2917217-B1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S A (PL) 2017-03-08 EP disclosed
EP-2917217-B1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S A (PL) 2017-03-08 EP disclosed
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2015-10-01 US disclosed
EP-2917217-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA S.A. (PL) 2015-09-16 EP disclosed
WO-2014072435-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2014-05-15 WO disclosed
WO-2014072435-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS SELVITA SA (PL) 2014-05-15 WO disclosed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
WO-2007018998-A2 TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed
WO-1994028863-A1 8-AMINO-1,2,3,4-TETRAHYDROQUINOLINES AS COUPLERS IN DYES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1994-12-22 WO disclosed
EP-0146370-B1 IMIDAZOQUINOLINES CONTAINING OTHER HETEROCYCLIC GROUPS JOHN WYETH & BROTHER LIMITED (GB) 1988-10-19 EP disclosed
US-4703044-A Imidazoquinolines containing other heterocyclic groups, useful as anti-ulcer or anti-secretory agents JOHN WYETH & BROTHER LIMITED (GB) 1987-10-27 US disclosed
EP-0146370-A2 Imidazoquinolines containing other heterocyclic groups JOHN WYETH & BROTHER LIMITED (GB) 1985-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators GRM2, GRM1, GRIN2B PARP1 4669/4885ACHE 2218/4885HSD17B10 2706/4885
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators GRM2, GRM1, GRIN2B PARP1 4669/4885ACHE 2218/4885HSD17B10 2706/4885
US-20150274726-A1 SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS CDK8, CDK18, CDK9 PARP1 1282/4885ACHE 3445/4885HSD17B10 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.